ZURA
Zura Bio Limited
Company Overview
| Mkt Cap | $536.08M | Price | $5.72 |
| Volume | 528.33K | Change | +1.24% |
| P/E Ratio | -10.2 | Open | $5.87 |
| Revenue | -- | Prev Close | $5.65 |
| Net Income | $-52.4M | 52W Range | $0.98 - $7.44 |
| Div Yield | N/A | Target | $15.86 |
| Overall | 60 | Value | -- |
| Quality | -- | Technical | 60 |
No chart data available
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33. Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.
Latest News
Zura Bio Reports 2025 Results, Extends Cash Runway Outlook
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZURA | $5.72 | +1.2% | 528.33K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |